LungVax

The aim of this study is to evaluate whether administration of ChAdOx2-lungvax-NYESO is better than control (no vaccine) at preventing or delaying the onset of cancer in people at risk of recurrent or new NSCLC.

Lung cancer is the UK’s third most common cancer and is diagnosed in 48,500 people every year. It is highly lethal, 18% of those diagnosed with lung cancer are alive at 5 years, the majority dying within 1 year of diagnosis. This corresponds to over 35,000 deaths from lung cancer every year in the UK.

The current standard of care treatment for stage IA/B non-small cell lung cancer (NSCLC) is primary surgery followed by surveillance imaging (excluding patients eligible for neo/adjuvant therapies). Of patients with stage I disease undergoing surgical resection alone, recurrence or new primary cancers occur in 25-30% within 5 years.  This represents a post-operative window for a preventive intervention, such as a vaccine designed to prevent a new independent primary lung cancer, or to prevent the relapse of previous stage 1 disease. 

We will use a vaccine targeting specific cancer mutations to activate a robust T cell response to recognise and kill cancer cells bearing these selected mutations.

590 patients in total will be enrolled, 30 in the Phase I dose-escalation part and 560 in the Phase II randomised part, 280 in each arm.  We expect to open recruitment in Q1 2026.